Safety concerns when using novel medications to treat alopecia

Hind M. Almohanna, Marina Perper, Antonella Tosti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Alopecia is often a cause of great concern to patients for cosmetic and psychologic reasons. The aim of treating non-scarring alopecias is to reduce hair loss and, to some extent, enhance hair regrowth. However, therapies for scarring alopecias are limited and aiming to halt disease progression. Nonetheless, available modalities of treatment come with numerous side effects. Areas covered: Many new treatments for non-scarring alopecias have been introduced in recent years. This review summarizes the safety concerns when using novel therapeutic modalities such as JAK inhibitors, hair transplantation, mesotherapy, oral minoxidil, platelet-rich plasma, microneedling, and 5α-reductase inhibitors for treating hair loss. A broad literature search was performed using PubMed and Google Scholar in April 2018 to compile published articles that reported the adverse effects of new therapeutic modalities for alopecia. Expert opinion: Although emerging therapeutic modalities for alopecia have demonstrated efficacy in hair regrowth and treating established disease, their safety profiles vary widely. When considering the new treatments for alopecia, physicians should weigh the potential benefits and risks of each treatment or combination treatment to ensure safe and successful outcomes.

Original languageEnglish (US)
Pages (from-to)1115-1128
Number of pages14
JournalExpert Opinion on Drug Safety
Volume17
Issue number11
DOIs
StatePublished - Nov 2 2018

Fingerprint

Alopecia
Safety
Hair
Therapeutics
Mesotherapy
Minoxidil
Platelet-Rich Plasma
Expert Testimony
Therapeutic Uses
PubMed
Cosmetics
Cicatrix
Disease Progression
Oxidoreductases
Transplantation
Physicians

Keywords

  • Alopecia
  • dutasteride
  • finasteride
  • hair loss
  • hair transplantation
  • JAK inhibitor
  • mesotherapy
  • microneedling
  • minoxidil
  • platelet rich plasma

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety concerns when using novel medications to treat alopecia. / Almohanna, Hind M.; Perper, Marina; Tosti, Antonella.

In: Expert Opinion on Drug Safety, Vol. 17, No. 11, 02.11.2018, p. 1115-1128.

Research output: Contribution to journalArticle

Almohanna, Hind M. ; Perper, Marina ; Tosti, Antonella. / Safety concerns when using novel medications to treat alopecia. In: Expert Opinion on Drug Safety. 2018 ; Vol. 17, No. 11. pp. 1115-1128.
@article{4a61bffbb98c41b392c82f8431eff256,
title = "Safety concerns when using novel medications to treat alopecia",
abstract = "Introduction: Alopecia is often a cause of great concern to patients for cosmetic and psychologic reasons. The aim of treating non-scarring alopecias is to reduce hair loss and, to some extent, enhance hair regrowth. However, therapies for scarring alopecias are limited and aiming to halt disease progression. Nonetheless, available modalities of treatment come with numerous side effects. Areas covered: Many new treatments for non-scarring alopecias have been introduced in recent years. This review summarizes the safety concerns when using novel therapeutic modalities such as JAK inhibitors, hair transplantation, mesotherapy, oral minoxidil, platelet-rich plasma, microneedling, and 5α-reductase inhibitors for treating hair loss. A broad literature search was performed using PubMed and Google Scholar in April 2018 to compile published articles that reported the adverse effects of new therapeutic modalities for alopecia. Expert opinion: Although emerging therapeutic modalities for alopecia have demonstrated efficacy in hair regrowth and treating established disease, their safety profiles vary widely. When considering the new treatments for alopecia, physicians should weigh the potential benefits and risks of each treatment or combination treatment to ensure safe and successful outcomes.",
keywords = "Alopecia, dutasteride, finasteride, hair loss, hair transplantation, JAK inhibitor, mesotherapy, microneedling, minoxidil, platelet rich plasma",
author = "Almohanna, {Hind M.} and Marina Perper and Antonella Tosti",
year = "2018",
month = "11",
day = "2",
doi = "10.1080/14740338.2018.1533549",
language = "English (US)",
volume = "17",
pages = "1115--1128",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Safety concerns when using novel medications to treat alopecia

AU - Almohanna, Hind M.

AU - Perper, Marina

AU - Tosti, Antonella

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Introduction: Alopecia is often a cause of great concern to patients for cosmetic and psychologic reasons. The aim of treating non-scarring alopecias is to reduce hair loss and, to some extent, enhance hair regrowth. However, therapies for scarring alopecias are limited and aiming to halt disease progression. Nonetheless, available modalities of treatment come with numerous side effects. Areas covered: Many new treatments for non-scarring alopecias have been introduced in recent years. This review summarizes the safety concerns when using novel therapeutic modalities such as JAK inhibitors, hair transplantation, mesotherapy, oral minoxidil, platelet-rich plasma, microneedling, and 5α-reductase inhibitors for treating hair loss. A broad literature search was performed using PubMed and Google Scholar in April 2018 to compile published articles that reported the adverse effects of new therapeutic modalities for alopecia. Expert opinion: Although emerging therapeutic modalities for alopecia have demonstrated efficacy in hair regrowth and treating established disease, their safety profiles vary widely. When considering the new treatments for alopecia, physicians should weigh the potential benefits and risks of each treatment or combination treatment to ensure safe and successful outcomes.

AB - Introduction: Alopecia is often a cause of great concern to patients for cosmetic and psychologic reasons. The aim of treating non-scarring alopecias is to reduce hair loss and, to some extent, enhance hair regrowth. However, therapies for scarring alopecias are limited and aiming to halt disease progression. Nonetheless, available modalities of treatment come with numerous side effects. Areas covered: Many new treatments for non-scarring alopecias have been introduced in recent years. This review summarizes the safety concerns when using novel therapeutic modalities such as JAK inhibitors, hair transplantation, mesotherapy, oral minoxidil, platelet-rich plasma, microneedling, and 5α-reductase inhibitors for treating hair loss. A broad literature search was performed using PubMed and Google Scholar in April 2018 to compile published articles that reported the adverse effects of new therapeutic modalities for alopecia. Expert opinion: Although emerging therapeutic modalities for alopecia have demonstrated efficacy in hair regrowth and treating established disease, their safety profiles vary widely. When considering the new treatments for alopecia, physicians should weigh the potential benefits and risks of each treatment or combination treatment to ensure safe and successful outcomes.

KW - Alopecia

KW - dutasteride

KW - finasteride

KW - hair loss

KW - hair transplantation

KW - JAK inhibitor

KW - mesotherapy

KW - microneedling

KW - minoxidil

KW - platelet rich plasma

UR - http://www.scopus.com/inward/record.url?scp=85055414449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055414449&partnerID=8YFLogxK

U2 - 10.1080/14740338.2018.1533549

DO - 10.1080/14740338.2018.1533549

M3 - Article

VL - 17

SP - 1115

EP - 1128

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 11

ER -